At CHEST 2014, Sunovion Pharmaceuticals Inc will present new data highlighting the efficacy and safety results from an investigational study of SUN-101 (glycopyrrolate inhalation solution) for patients with moderate-to-severe COPD.
SUN-101 is a long-acting muscarinic antagonist (LAMA) bronchodilator in development for the treatment of COPD that will be delivered via the PARI’s eFlow nebulizer system. There are currently no nebulized LAMAs available on the market, according to Sunovion.
